Drugs that may trigger AHA in G6PD-deficient patients
Definite risk of AHA . | “Possible” risk of AHA . | Possible association (less likely) . |
---|---|---|
Antimalarial drugs | ||
Dapsone-containing combinations* | Chloroquine | |
Pamaquine* | Quinidine | |
Primaquine* | Quinine | |
Tafenoquine | ||
Other drugs | ||
Ciprofloxacin | Aspirin† | Chloramphenicol |
Glibenclamide‡ | Menadiol sodium phosphate | Dimercaptosuccinic acid |
Methylthioninium chloride*,§ | Sulfadiazine | Glibenclamide |
Moxifloxacin | Sulfasalazine | Mepacrine |
Nalidixic acid | Sulfonylureas | Vitamin K analogs |
Niridazole | Tolonium chloride|| | |
Nitrofurantoin*,¶ | ||
Norfloxacin | ||
Ofloxacin | ||
Phenazopyridine# | ||
Rasburicase and pegloticase34,* | ||
Sulfamethoxazole/ cotrimoxazole | ||
Henna (cosmetic use)35-37 |
Definite risk of AHA . | “Possible” risk of AHA . | Possible association (less likely) . |
---|---|---|
Antimalarial drugs | ||
Dapsone-containing combinations* | Chloroquine | |
Pamaquine* | Quinidine | |
Primaquine* | Quinine | |
Tafenoquine | ||
Other drugs | ||
Ciprofloxacin | Aspirin† | Chloramphenicol |
Glibenclamide‡ | Menadiol sodium phosphate | Dimercaptosuccinic acid |
Methylthioninium chloride*,§ | Sulfadiazine | Glibenclamide |
Moxifloxacin | Sulfasalazine | Mepacrine |
Nalidixic acid | Sulfonylureas | Vitamin K analogs |
Niridazole | Tolonium chloride|| | |
Nitrofurantoin*,¶ | ||
Norfloxacin | ||
Ofloxacin | ||
Phenazopyridine# | ||
Rasburicase and pegloticase34,* | ||
Sulfamethoxazole/ cotrimoxazole | ||
Henna (cosmetic use)35-37 |
Modified from Table 4 of Luzzatto et al,38 where sources and additional references are given.
Evidence-based according to Youngster et al.39
Acetylsalicylic acid. Like for all drugs, hemolysis is dose-related. The regimen of 75 to 100 mg per day, widely used for the prophylaxis of cardiovascular events, is safe for G6PD-deficient persons.
Glyburide.
Methylene blue.
Toluidine blue.
Furadantin.
Pyridium.